Lung cancer management in 2010

Apar Kishor P Ganti, Chao H. Huang, Mark A. Klein, Sean Keefe, Michael J. Kelley

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

Original languageEnglish (US)
JournalONCOLOGY
Volume25
Issue number1
StatePublished - Jan 2011

Fingerprint

Lung Neoplasms
Cytotoxins
Patient Care
Clinical Trials
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ganti, A. K. P., Huang, C. H., Klein, M. A., Keefe, S., & Kelley, M. J. (2011). Lung cancer management in 2010. ONCOLOGY, 25(1).

Lung cancer management in 2010. / Ganti, Apar Kishor P; Huang, Chao H.; Klein, Mark A.; Keefe, Sean; Kelley, Michael J.

In: ONCOLOGY, Vol. 25, No. 1, 01.2011.

Research output: Contribution to journalReview article

Ganti, AKP, Huang, CH, Klein, MA, Keefe, S & Kelley, MJ 2011, 'Lung cancer management in 2010', ONCOLOGY, vol. 25, no. 1.
Ganti AKP, Huang CH, Klein MA, Keefe S, Kelley MJ. Lung cancer management in 2010. ONCOLOGY. 2011 Jan;25(1).
Ganti, Apar Kishor P ; Huang, Chao H. ; Klein, Mark A. ; Keefe, Sean ; Kelley, Michael J. / Lung cancer management in 2010. In: ONCOLOGY. 2011 ; Vol. 25, No. 1.
@article{1f3bb78008b846fc92d2ae7b767a3135,
title = "Lung cancer management in 2010",
abstract = "The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.",
author = "Ganti, {Apar Kishor P} and Huang, {Chao H.} and Klein, {Mark A.} and Sean Keefe and Kelley, {Michael J.}",
year = "2011",
month = "1",
language = "English (US)",
volume = "25",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Lung cancer management in 2010

AU - Ganti, Apar Kishor P

AU - Huang, Chao H.

AU - Klein, Mark A.

AU - Keefe, Sean

AU - Kelley, Michael J.

PY - 2011/1

Y1 - 2011/1

N2 - The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

AB - The introduction of newer therapies and approaches for management has led to a renewed excitement in the field of lung cancer. This trend has continued in 2010 with the adoption of the new staging system recommended by the International Association for the Study of Lung Cancer (IASLC). Novel targets, such as EML4-ALK, have been identified and agents targeting these abnormalities have shown promise in uncontrolled clinical trials, while other strategies, including combining targeted agents with cytotoxic chemotherapy in unselected patients, have not proven to be successful. This review summarizes important recent clinical advances that could have a significant impact on the future care of patients with lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=79551718343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551718343&partnerID=8YFLogxK

M3 - Review article

C2 - 21361246

AN - SCOPUS:79551718343

VL - 25

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1

ER -